Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis

Matthias Nahrendorf, MD*; Farouc A. Jaffer, MD, PhD*; Kimberly A. Kelly, PhD; David E. Sosnovik, MD; Elena Aikawa, MD, PhD; Peter Libby, MD; Ralph Weissleder, MD, PhD

Background—Noninvasive imaging of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) may identify early stages of inflammation in atherosclerosis. We hypothesized that a novel, second-generation VCAM-1–targeted agent with enhanced affinity had sufficient sensitivity to enable real-time detection of VCAM-1 expression in experimental atherosclerosis in vivo, to quantify pharmacotherapy-induced reductions in VCAM-1 expression, and to identify activated cells in human plaques.

Methods and Results—In vivo phage display in apolipoprotein E–deficient mice identified a linear peptide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1. This peptide was developed into a multivalent agent detectable by MRI and optical imaging (denoted VINP-28 for VCAM-1–targeted nanoparticle 28, with 20 times higher affinity than previously reported for VNP). In vitro, VINP-28 targeted all cell types expressing VCAM-1. In vivo, MRI and optical imaging in apolipoprotein E–deficient mice (n=28) after injection with VINP-28 revealed signal enhancement in the aortic root of mice receiving VINP-28 (P<0.05). VINP-28 colocalized with endothelial cells and other VCAM-1–expressing cells, eg, macrophages, and was spatially distinct compared with untargeted control nanoparticles. Atheromata of atorvastatin-treated mice showed reduced VINP-28 deposition and VCAM-1 expression. VINP-28 enhanced early lesions in juvenile mice and resected human carotid artery plaques.

Conclusions—VINP-28 allows noninvasive imaging of VCAM-1–expressing endothelial cells and macrophages in atherosclerosis and spatial monitoring of anti–VCAM-1 pharmacotherapy in vivo and identifies inflammatory cells in human atheromata. This clinically translatable agent could noninvasively detect inflammation in early, subclinical atherosclerosis. (Circulation. 2006;114:1504-1511.)

Key Words: atherosclerosis ■ cell adhesion molecules ■ imaging ■ inflammation ■ magnetic resonance imaging

Despite advances in cardiovascular care, the prevalence of atherosclerosis and its complications, myocardial infarction and stroke, is increasing worldwide.1 Current noninvasive tools to assess atherosclerosis and effects of treatments rely almost entirely on structural, anatomic features of lesions. Noninvasive molecular imaging of atherosclerosis2–5 could enable a novel biologically based approach beyond anatomy to identify vulnerable patients and to evaluate the effects of interventions, including emerging therapies. For example, inflammation appears to drive many aspects of atherogenesis and its clinical complications.6 However, current imaging modalities disclose minimal information about this key biological process.

Clinical Perspective p 1511

Vascular cell adhesion molecule-1 (VCAM-1) (CD106), an immunoglobulin superfamily glycoprotein (100 to 110 kDa) expressed on activated endothelial cells, macrophages, and smooth muscle cells (SMCs),7–9 participates in the inflammatory initiation and progression of atherosclerotic plaques.6,8,10–13 VCAM-1 mediates adhesion of leukocytes to endothelial cells and facilitates their transmigration to the nascent atheromata. Furthermore, genetically modified mice with impaired VCAM-1 function have reduced atherosclerotic lesion formation.13 Treatment with HMG-CoA reductase inhibitors14 or angiotensin receptor blockers15 reduces VCAM-1 expression in experimental atherosclerosis.

Received February 2, 2006; de novo received June 16, 2006; accepted July 31, 2006.

From the Center for Molecular Imaging Research (M.N., F.A.J., K.A.K., D.E.S., E.A., R.W.) and Cardiology Division, Department of Medicine (F.A.J., D.E.S.), Massachusetts General Hospital; Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital (P.L.); and Donald W. Reynolds Cardiovascular Clinical Research Center, Harvard Medical School (M.N., F.A.J., K.A.K., E.A., P.L., R.W.), Boston, Mass.

Guest Editor for this article was John F. Keaney, Jr, MD.

The online-only Data Supplement is available at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.106.646380/DC1.

*The first 2 authors contributed equally to this work.

Correspondence to Farouc Jaffer, MD, PhD, or Ralph Weissleder, MD, PhD, MGH-CMIR, 149 13th St, Room 5406, Charlestown, MA 02129. E-mail fjaffer@partners.org or Weissleder@helix.mgh.harvard.edu

© 2006 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org DOI: 10.1161/CIRCULATIONAHA.106.646380

1504
pharmacologically mediated reductions in VCAM-1; (3) facilitate imaging of early murine atherosclerosis; and (4) detect VCAM-1–expressing cells in human atheromata.

Methods

Materials; experiments investigating uptake of VINP-28 into cultured endothelial cells, macrophages, and SMCs; fluorescence reflectance imaging of resected aortas; histopathological analysis; immunoblotting; and serum cholesterol measurements are described in the online-only Data Supplement.

Nanoparticles

The MNP used in this study was a monocryostalline MNP consisting of a 3-nm core, an overall size of 38 nm, and an R2 of 62 mM−1s−1 that had an average of 62 primary amines available for conjugation.17 Further details and peptide synthesis and conjugation are available in the online-only Data Supplement. An additional control NP (CLIO-AF750) was similar to CLIO-Cy5.5 (excitation/emission, 673/694 nm) except for containing a spectrally distinct fluorochrome (excitation/emission, 752/779 nm).

In Vivo Phage Display for Target Identification

A linear VCAM-1–targeting peptide was identified via in vivo phage display in apolipoprotein E–deficient (apoE−/−) mice.18 Briefly, an M13 phage library (2 × 109 individual clones) consisting of randomized linear peptides of 7 amino acids (New England Biolab, Beverly, Mass) was injected into the tail vein of cholesterol-fed apoE−/− mice. Internalized phages were retrieved from dissected aortic plaques and then reinjected into subsequent mice for a total of 3 rounds of positive selection. Recovered phages were plated and individual clones sequenced. The peptide sequence VHPKQHR represented >10% of the library. By BLAST search, the peptide was noted to be homologous to the very late antigen-4, a known ligand of VCAM-1,16 and was thus chosen for specificity testing and subsequent probe synthesis.

Intravital Microscopy of VCAM-1 Expression in Tumor Necrosis Factor-α–Induced Ear Inflammation

C57BL/6 mice (n = 3) were injected subcutaneously in the right ear with tumor necrosis factor (TNF)-α (5 ng in 50 μL normal saline, R&D Systems, Minneapolis, Minn) as described previously.16 Animals were injected intravenously with 5 mmol/L fluorochrome of VINP-28, as well as an intravascular imaging agent (Angioense, 750, VisEn, Woburn, Mass). Intravital microscopy is described in detail in the online-only Data Supplement.

Imaging of Atherosclerotic Mice

A total of 67 mice were used in this study (imaging experiments: 28 apoE−/− mice, 32 weeks of age; 3 apoE−/− mice, 9 weeks of age; 13 C57BL/6 mice; phage display, feasibility, dose-finding studies, and Western blot: 23 apoE−/− mice). ApoE−/− mice received a high-cholesterol diet (HCD; Harlan Teklad, Madison, Wis; 0.2% total cholesterol) for 22 weeks. All animals received VINP-28 or control NP intravenous injections (30 mg Fe/kg) 48 hours before imaging. Three experimental groups were investigated. In the validation trial, 15 mice were injected with VINP-28, 2 mice were cojected with VINP-28 and an underivatized control NP (CLIO-AF750), and 3 mice were injected with saline. In the statin treatment group, 8 mice were randomized to receive 8 weeks of HCD enriched with 0.01% wt/wt of atorvastatin.19 In the early atherosclerosis group, 3 apoE−/− mice were imaged at the 9 weeks of age after 2 weeks of an HCD. The institutional subcommittee on research animal care approved all animal studies.

MRI Studies

In vivo MRI studies were performed on a 9.4-T horizontal-bore scanner (Bruker Biospec, Billerica, Mass). Bright-blood cine images
were obtained with ECG and respiratory gating (SA Instruments, Stony Brook, NY) using a gradient-echo FLASH sequence and a dedicated mouse cardiac surface coil. A short-axis slice through the aortic root was identified. Care was taken to ensure that all 3 aortic valve cusps were clearly visualized to provide fiducial landmarks for coregistration with subsequent MR images and with images from other modalities. Imaging parameters and image analysis are described in the online-only Data Supplement.

Fluorescence Microscopy
The cellular distribution of VINP-28 and control NPs in atheroma was assessed with multichannel fluorescent microscopy. Sections were imaged with an upright epifluorescent microscope (Eclipse 80i, Nikon, New York, NY) with a cooled CCD camera (Cascade, Photometrics, Tucson, Ariz) at a wavelength of 710 nm (for VINP-28) and 780 nm (for untargeted NP). Exposure times ranged from 100 to 2000 ms, depending on the channel.

Human Carotid Artery Specimens
Freshly resected carotid endarterectomy specimens were immediately placed in Dulbecco’s modified Eagle’s medium under sterile conditions. The specimens were incubated with either VINP-28 or buffer for 24 hours at 37°C. The T2 relaxation time was determined before and after incubation with a minispectrometer (Bruker), and fluorescence reflectance imaging was performed. Thereafter, the sections were embedded in OCT and processed for correlative fluorescence microscopy and immunohistochemistry.

Statistical Analysis
Results are expressed as mean±SD. Statistical comparisons between 2 groups were evaluated by Student t test and corrected by ANOVA for multiple comparisons. A value of P<0.05 was considered statistically significant.

The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.

Results
VINP-28 Targets VCAM-1–Expressing Cells
Iterative in vivo phage display identified the linear peptide VHPKQHR as homologous but not identical to a peptide identified on a previous in vitro screen using a disulfide-constrained library on endothelial cells (the Table). We compared the peptide sequences isolated through the in vivo screen to the previous in vitro phage display with the RELIC software (shareware) and found a 47% overlap in consensus families. Among such families, 27% were strictly confined to the in vivo screen and 26% to the in vivo screen.

The peptide sequence was synthetically extended at its amine terminal and conjugated in multivalent form (12 copies per NP) to yield VINP-28 (Figure 1A). Soluble VCAM-1 blocked endothelial uptake of VINP-28 at low concentrations (Figure 1B). Among primary murine endothelial cells, SMCs, and macrophages, VINP-28 had the highest affinity for endothelial cells, with relatively lower levels of accumulation in SMCs and macrophages, cells known to express variable...
levels of VCAM-1 in mice2 (Figure 1C). A direct comparison with a first-generation version of the agent (VNP) showed a 20-fold improvement in flow cytometric signal (410.4 mean fluorescence units for VNP-28 versus 19.4 mean fluorescence units for VNP; \( P < 0.001 \)). In the inflamed ear preparation, intravital microscopy showed strong enhancement in VCAM-1–positive vascular endothelium, as defined by the coinjected intravascular dye (Figure 1D through 1H). VNP-28 was injected into C57BL/6 mice to determine blood half-life and biodistribution. The blood half-life in mice was 17.7 hours and the organ distribution 6 hours after injection was as follows (percent injected dose [ID]): liver, 2.83±0.53 ID/g; spleen, 0.82±0.19 ID/g; kidneys, 1.87±0.14 ID/g; heart, 0.90±0.18 ID/g; lungs, 0.77±0.15 ID/g; fat, 0.20±0.28 ID/g; and muscle, 0.22±0.16 ID/g.

**VINP-28 Selectively Targets VCAM-1–Expressing Cells in Atheroma**

We next determined whether the cellular localization of VINP-28 in atherosclerotic lesions was distinct from clinical-type control NPs that primarily target macrophages in atheroma.20–22 Coinjection of VINP-28-Cy5.5 and NP-AF750 into the same apoE \(^{-/-}\) mice revealed that VINP-28 strongly accumulated in the endothelial layer and subendothelial plaque regions (Figure 2A) and was distinct from control NPs (Figure 2B). Fluorescence microscopy of the distribution of VINP-28 correlated well with immunohistochemistry for VCAM-1 expression (Figure 2C through 2E; \( r^2 = 0.87, P < 0.005; n = 7 \)). VINP-28 targeted endothelial cells and macrophages that expressed VCAM-1 (Figure 3). We determined that 94±2% of endothelial cells and 58±4% of macrophages contained VINP-28. These cells also stained positive for VCAM-1 in adjacent sections (Figure 3).

**Noninvasive MR Imaging of VCAM-1 Expression**

We next determined the ability of VINP-28 to assess VCAM-1 expression noninvasively in atherosclerosis. In particular, the aortic root, an expected area of atherosclerosis in apoE \(^{-/-}\) mice,23 showed high VINP-28 uptake and change in MRI signal (Figure 4A and 4B). The contrast-to-noise ratio between the aortic wall and adjacent blood pool increased on average by 77%, driven by a decrease in signal intensity in the aortic wall \( (P < 0.05; \text{Figure 4A and 4B}) \). The in vivo MR findings correlated with the fluorescent reflectance images of resected aortas, which showed a strong fluorescent signal from VINP-28 in aortic atheroma. The aortic root yielded a high plaque target-to-background ratio of 9.2±2.5 (>350% higher than in saline-injected apoE \(^{-/-}\) mice; \( P < 0.05 \); Figure 4C through 4F).

**VINP-28 Detects Reductions in VCAM-1 Expression Produced by Statin Treatment**

To determine the ability of VINP-28 to monitor pharmacotherapy for atherosclerosis, we imaged apoE \(^{-/-}\) mice that consumed an atherogenic diet without or with admixed atorvastatin (Figure 5). Eight weeks of statin treatment reduced serum cholesterol moderately, as expected, in mice (HCD, 601±34 mg/dL; HCD plus atorvastatin, 506±79 mg/dL; \( P < 0.05 \)). Statin-treated mice exhibited minimal vessel wall enhancement after VINP-28 injection (blood-plaque contrast-to-noise ratio before injection, 21.4±5.5; after injec-


**Figure 5.** Noninvasive MRI assessment of VCAM-1 expression after atorvastatin administration. A, Short-axis MRI of the aortic root of an untreated apoE−/− mouse on an HCD after VINP-28 injection with color-coded signal intensity. B, MRI of HCD–atorvastatin apoE−/− mouse after VINP-28 injection. An attenuated signal drop in the aortic root wall compared with untreated mouse was noted. The red color encodes high VCAM-1 expression. C, After injection of VINP-28, the MRI contrast-to-noise ratio diminished in atorvastatin-treated mice (mean±SD; *P<0.05 vs HCD). D, E, NIR microscopy of aortic root depicted in A and B. Fluorescent signal originating from VINP-28 comprised the whole-root circumference (D), but less so in atorvastatin-treated mice (E). F, H, Fluorescent reflectance imaging of the excised aorta of an untreated (F) and atorvastatin-treated (G) mouse showed reduced NIR signal in statin-treated mice. The target-to-background ratio was reduced in aortas of treated mice (H; mean±SD; *P<0.05 treated vs untreated mice).

**Figure 6.** Assessment of atorvastatin treatment by invasive measures. A–E, Treatment with atorvastatin led to reduced probe uptake as assessed by fluorescence microscopy (A, untreated; C, treated) and a decreased immunohistochemistry staining for VCAM-1 (B, untreated; D, treated). The root area with positive immunohistochemical detection of VCAM-1 was smaller in atorvastatin-treated mice (E; *P<0.05). F, Western blotting corroborated reduced VCAM-1 expression in statin-treated mice (*P<0.05). WT indicates wild type; AU, arbitrary units.

tion, 22.9±7.0, *P=*NS; Figure 5B), consistent with reduced VCAM-1 expression in the aortic root of statin-treated mice. In contrast, the plaque-blood contrast-to-noise ratio differed substantially in HCD-only mice (HCD, 37.9±3.5; HCD plus atorvastatin, 22.9±7.0; *P<0.05; Figure 5A through 5C).

By fluorescent reflectance imaging, statin-treated animals had significantly less VINP-28–associated near-infrared fluorescence (NIRF) signal (Figure 5F through 5H; target-to-background ratio, 4.9±1.6 versus 9.3±3.8, *P<0.05). Fluorescence microscopy showed only slight VINP-28 uptake in aortic roots of statin-treated mice (Figure 5D and 5E). We quantified the NIRF signal in aortic root sections and normalized it by total plaque area. This index decreased significantly in statin-treated mice (HCD, 18.5±2.1; HCD plus atorvastatin, 4.1±1.8 [arbitrary units]; *P<0.01), thus demonstrating that the atorvastatin-related MRI signal changes did not depend primarily on changes in lesion size. VINP-28 imaging findings in statin-treated animals correlated well with VCAM-1 reductions as measured by immunohistochemistry and immunoblotting (Figure 6).

**Imaging of VCAM-1 Expression in Early Atheroma**

Because arterial VCAM-1 expression increases early in atherogenesis, it might serve as a useful target for molecular imaging of subclinical disease. We therefore determined whether VINP-28–enhanced imaging could detect early atherosclerotic lesions in juvenile apoE−/− mice (age, 9 weeks) that consumed an HCD for only 2 weeks. Indeed, VINP-28 enhanced early atheroma in the aortic root, aortic arch, and proximal great vessels; distal carotid arteries; abdominal aorta at the level of the renal arteries; and iliac arteries (Figure 7). By reflectance imaging, the plaque target-to-background ratio was 61% higher than in saline-injected mice (*P<0.05). By fluorescence microscopy, VINP-28 enhanced early lesions and colocalized with VCAM-1 in endothelial cells and macrophages (Figure 7C through 7G), as seen in older apoE−/− mice.

**VINP-28 Identifies VCAM-1–Expressing Cells in Human Carotid Atheroma Ex Vivo**

To investigate the ability of VINP-28 to target human VCAM-1 expression in atherosclerosis, the agent or saline was incubated with freshly resected human carotid endarterectomy specimens (n=2). VINP-28 induced changes in the MR signal in atheroma. After 24 hours, samples incubated with saline exhibited a T2 increase of 1.5±1 ms. In contrast, plaque sections incubated with VINP-28 demonstrated a T2 reduction of 3.8±1.7 ms (*P<0.05 versus saline), consistent with VINP-28 uptake by the specimen. Fluorescence imaging showed strong plaque enhancement in VINP-28–incubated samples (Figure 8A and 8B). Microscopy revealed that...
VINP-28 colocalized with VCAM-1–expressing cells as assessed by immunohistochemistry (Figure 8C and 8D).

**Discussion**

Expression of the adhesion molecule VCAM-1 occurs early during atherogenesis and thus may serve as a useful imaging biomarker for inflammation in atherosclerosis. Here, we demonstrate that the novel imaging agent VINP-28 allows in vivo assessment of VCAM-1 in mouse atherosclerotic plaques. The multivalent MRI agent, targeted by a peptide sequence identified via in vivo phage selection, selectively visualized both murine and human VCAM-1. VINP-28 enhanced atheroma on noninvasive MRI, allowed assessment of modulated VCAM-1 levels in response to an intervention, detected early atheromata (fatty streak–like lesions), and targeted VCAM-1–expressing cells of human carotid atherosclerotic plaques. Multimodality MRI and NIRF imaging findings correlated closely with VCAM-1 expression as disclosed by immunohistochemistry and immunoblotting. The specific agent and the generic approach used in its discovery may represent valuable tools for expanded in vivo imaging of molecular targets in atherosclerosis.

Facilitated by the fluorescent properties of NPs, we found that VINP-28 targets endothelial cells and macrophages that express VCAM-1 (Figure 3). Previous reports established the expression of VCAM-1 by these cell types and VINP-28 also labeled macrophages and SMCs in vitro, although to a lesser degree than endothelial cells. Therefore, VINP-28 reports on the cellular content of all cells that express VCAM-1, including endothelial cells and macrophages. Because macrophages outnumber endothelial cells in inflamed atherosclerotic lesions, they may contribute considerably to MRI contrast enhancement in vivo through VCAM-1–facilitated probe uptake.

We identified the peptide affinity ligand sequence with in vivo phage display technology. Compared with a previous in vitro screen on endothelial cells, the motif overlap (47%) likely indicates specificity of those sequences for endothelial targets. Differences in the 2 screens explain the remaining nonmatching motifs; although we used only 1 cell type in the in vitro experiment (murine cardiac endothelial cells), the current display exposed the phages to the in vivo milieu of atherosclerotic plaques, thus introducing more complexity with respect to pharmacokinetic barriers and additional cell types.

VINP-28 is a model magnetofluorescent NP with favorable biophysical properties. The NP contains a superparamagnetic iron oxide core and a stable, biodegradable coating that permits surface attachment of peptides. Similar preparations (with cross-linked polymer coating) have shown low toxicity in clinical trials and are biodegradable. VINP-28 has an R2 of 62 mM⁻¹s⁻¹ in aqueous solution, allowing sensitive detection by MRI. Additional factors further boosted the MRI-detectable signal: Cellular internalization of VINP-28 leads to “trapping” (active accumulation) and a relaxation switch effect, effectively increasing R2 in tissue to >250 mM⁻¹s⁻¹. Cellular internalization and retention is a powerful biological amplification strategy that can enhance visual-
Vascular cell adhesion molecule-1 participates in cardiovascular tissue remodeling and a number of inflammatory diseases, including atherogenesis, transplant rejection, allograft arteriosclerosis, asthma and cancer. VCAM-1 therefore represents an attractive imaging and potential therapeutic target beyond atherosclerosis. Assessment of VCAM-1 expression by VNP-28–enhanced MRI offers a sensitive and noninvasive approach to test novel VCAM-1–targeted therapies. Its usefulness for pharmaceutical development could involve serial imaging studies that assess VCAM-1 expression before and after treatment with a novel candidate therapy. In atherosclerosis, VNP-28 can noninvasively detect statin-associated decreases in VCAM-1 expression in apoE−/− mice (Figure 5). Immunohistochemical studies, Western blotting, and NIFIR imaging confirmed reduced VCAM-1 expression in the statin group. These findings agree with earlier histopathological studies that demonstrated a statin-associated decrease in VCAM-1 expression in atheromas of nonhuman primates, rabbits and mice.

Molecular imaging methods to detect atherosclerotic lesions can potentially improve diagnosis, risk stratification, and therapy of patients with atherosclerosis. By providing a noninvasive biological readout of inflammation in atherosclerosis, VNP-28–enhanced MRI could offer complementary information to structural imaging methods. The early expression of the target molecule in the time course of the disease and the excellent avidity of VNP-28 achieved by several amplification strategies allow identification of very early stages of atherosclerosis, as demonstrated in juvenile apoE−/− mice. VNP-28 also enhanced VCAM-1–expressing cells in human plaques (Figure 8). On a translational level, VNP-28 may thus detect not only the presence of atherosclerotic lesions but also their degree of inflammatory activation, an important mechanism implicated in clinical complications of atherosclerosis leading to events such as myocardial infarction and stroke. Early detection of inflamed plaques could identify the high-risk individual who may warrant intensive risk reduction.

Acknowledgments

We thank members of the CMIR Chemistry Core, including Drs Fred Reynolds for the conjugation of peptides, Nikolay Sergeyev for the synthesis of CLIO-CY5.5 and CLIO-AF750, and Lee Josephson for many helpful discussions. We acknowledge the CMIR Pathology Core (Vincent Lok, BS) for assistance with histology; Dr Masanori Aikawa and Manabu Minami for supplying murine aortic SMCs; Kelly Kristof, BA, and Dr Ashvin Pande for cell culture experiments; Drs Glenn LaMuraglia and Christopher Kwok, MGH Vascular Surgery, and Matthew Spotnitz, MS, for assistance in obtaining carotid endarterectomy specimens; Dr Rainer Kohler for intravital microscopy; and Dr Guangping Dai, Martinsen Center for Biomedical Imaging.

Sources of Funding

This work was supported by the Donald W. Reynolds Foundation (Drs Libby, Weissleder, Jaffer, Nahrendorf, and Aikawa), ROI-HL078641 (Dr Weissleder), ROI-HL36436 (Dr Libby), UO1-HL08731 (Dr Weissleder), and P01-AI 54904 (Dr Weissleder).

Disclosures

None.

References

Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis

Matthias Nahrendorf, Farouc A. Jaffer, Kimberly A. Kelly, David E. Sosnovik, Elena Aikawa, Peter Libby and Ralph Weissleder

_Circulation_. 2006;114:1504-1511; originally published online September 25, 2006; doi: 10.1161/CIRCULATIONAHA.106.646380

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2006 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/114/14/1504

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2006/09/21/CIRCULATIONAHA.106.646380.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/